Your browser doesn't support javascript.
Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
Xu, Yanlan; Yang, Xinyu; Bian, Hua; Xia, Mingfeng.
  • Xu Y; Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Yang X; Department of Geriatrics, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, 201700, China.
  • Bian H; Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Xia M; Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. bianhuaer@126.com.
Lipids Health Dis ; 20(1): 126, 2021 Oct 03.
Article in English | MEDLINE | ID: covidwho-2196306
ABSTRACT
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). At present, the COVID-19 has been prevalent worldwide for more than a year and caused more than four million deaths. Liver injury was frequently observed in patients with COVID-19. Recently, a new definition of metabolic dysfunction associated fatty liver disease (MAFLD) was proposed by a panel of international experts, and the relationship between MAFLD and COVID-19 has been actively investigated. Several previous studies indicated that the patients with MAFLD had a higher prevalence of COVID-19 and a tendency to develop severe type of respiratory infection, and others indicated that liver injury would be exacerbated in the patients with MAFLD once infected with COVID-19. The mechanism underlying the relationship between MAFLD and COVID-19 infection has not been thoroughly investigated, and recent studies indicated that multifactorial mechanisms, such as altered host angiotensin converting enzyme 2 (ACE2) receptor expression, direct viral attack, disruption of cholangiocyte function, systemic inflammatory reaction, drug-induced liver injury, hepatic ischemic and hypoxic injury, and MAFLD-related glucose and lipid metabolic disorders, might jointly contribute to both of the adverse hepatic and respiratory outcomes. In this review, we discussed the relationship between MAFLD and COVID-19 based on current available literature, and summarized the recommendations for clinical management of MAFLD patients during the pandemic of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemical and Drug Induced Liver Injury / Non-alcoholic Fatty Liver Disease / SARS-CoV-2 / COVID-19 / Liver / Hypoxia / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study Topics: Long Covid Language: English Journal: Lipids Health Dis Journal subject: Biochemistry / Metabolism Year: 2021 Document Type: Article Affiliation country: S12944-021-01564-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemical and Drug Induced Liver Injury / Non-alcoholic Fatty Liver Disease / SARS-CoV-2 / COVID-19 / Liver / Hypoxia / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study Topics: Long Covid Language: English Journal: Lipids Health Dis Journal subject: Biochemistry / Metabolism Year: 2021 Document Type: Article Affiliation country: S12944-021-01564-z